CDK Inhibitor Combinations Targeting Cancer Cell Antioxidant Defenses

The patent combines CDK inhibitors with antioxidant enzyme inhibitors (such as thioredoxin reductase inhibitors or glutathione system inhibitors) into a single pharmaceutical composition. This merging of two different therapeutic mechanisms allows the composition to simultaneously target cell proliferation control and reduce antioxidant enzyme levels, thereby overcoming the limitation of using CDK inhibitors alone and improving overall therapeutic efficacy against cancer cells with high antioxidant defenses.

The patent merges multiple therapeutic agents (CDK inhibitor and antioxidant enzyme inhibitor) into a single pharmaceutical composition that can be administered as one unified treatment. This approach maintains the synergistic benefits of combination therapy while simplifying the treatment protocol, as the combined composition eliminates the need for separate administration schedules and monitoring protocols for each individual agent.

The patent employs antioxidant enzyme inhibitors that specifically target cancer cells through mechanisms such as selective uptake, activation by cancer cell metabolites, or targeting of cancer-specific antioxidant enzymes. This local quality approach ensures that oxidative stress is primarily generated within the cancer cell environment where it promotes apoptosis, while normal cells with lower antioxidant enzyme levels and different metabolic profiles are spared from excessive oxidative damage.

The patent combines multiple therapeutic agents into a single pharmaceutical composition with a unified formulation and manufacturing process. This merging approach maintains the advantage of targeting multiple biological mechanisms to prevent drug resistance, while simplifying manufacturing by eliminating the need for separate production lines, quality control procedures, and logistics management for multiple individual agents.